Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 13;16(9):e69356.
doi: 10.7759/cureus.69356. eCollection 2024 Sep.

Synucleins As Biomarkers of Severity in Autism Spectrum Disorder

Affiliations

Synucleins As Biomarkers of Severity in Autism Spectrum Disorder

Lal D V Nair et al. Cureus. .

Abstract

Introduction Autism spectrum disorder (ASD) is a lifelong disorder affecting children quite early in life, manifested as delays in communication and stereotypic behaviors. To date, it is diagnosed clinically using the Diagnostic and Statistical Manual-5 (DSM-V) criteria due to the lack of biomarkers that can specifically denote the disorder. The role of synucleins in this context has been considered due to the increasing evidence of neurodegeneration in many autistic children. Synucleins are a group of soluble neuronal proteins primarily expressed in the central nervous system. They are of three types: α-, β-, and ɣ-synuclein. α-synuclein is involved in vesicle trafficking and release of neurotransmitters. There is no uniformity in the scientific community regarding their levels of autism, with few studies showing increasing levels and others to the contrary. Hence, the present study was conceived to analyze the levels of α-synuclein and β-synuclein in autistic children and to correlate with the disease severity. Objectives The main objective of the study was to assess the levels of α- and β-synuclein in autistic children of 2-8 years of age and to identify the correlation between the severity of core symptoms of autism and α- and β-synuclein levels. It is intended to assess the possibility of using α- and β-synuclein/their ratio as a biomarker of the severity of autism. Materials and methods Plasma levels of α-synuclein and β-synuclein were measured in 160 ASD children and 40 healthy age and sex-matched children by ELISA. Their symptom severity was assessed with CARS-2 ST and the Indian Scale of Autism Assessment (ISAA). Values of α- and β-synuclein were analyzed for correlation with the severity rating of ASD. Cut-off values of α-synuclein and β-synuclein that discriminate the presence of autism and its severity were assessed using Jamovi 2.4.14 software. Results The results show that α-synuclein levels were significantly reduced (5.02 ± 0.586; range: 3.13-6.0 ng/ml) when compared with healthy controls (29.47 ± 18.62 ng/ml; range: 22.39- 36.56) with p < 0.001, and β-synuclein levels were elevated (1424 ng/ml ± 122; range: 1229-1616 ng/ml) when compared to control, though not significantly. Plasma levels of α-synuclein significantly correlate with disease severity with good diagnostic accuracy (86%), but β-synuclein levels did not correlate with severity. The fold changes of synucleins, especially the fold decrease in levels of α-synuclein, were discriminative for the diagnosis and severity with good sensitivity (93.6%), specificity (74.3%), positive predictive (92.6%), and negative predictive values (76.5%). The fold increase in β-synuclein did not have any significance in predicting the severity of autism. Conclusion The present study showed that α-synuclein and β-synuclein were associated with ASD and can be used to assess its severity. A fold decrease in α-synuclein was found to have good discriminating value in differentiating the severity of autism. It may be of use especially in mild and high-functioning autism, when clinically distinguishing them may be difficult.

Keywords: alpha-synuclein; autism biomarker; autism spectrum disorder (asd); beta-synuclein; childhood autism rate scale; circulating biomarker; serum biomarker.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee of Saveetha Medical College and Hospital issued approval 003/06/2021/IEC/SMCH. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Boxplot analysis of ISAA and CARS-2 ST grades with synucleins and their fold changes
Median (horizontal line inside box), 25th and 75th centiles (lower and upper margin of the box), and outliers (dots or values outside the box). ISAA: Indian Scale of Autism Assessment; CARS-2 ST: childhood autism rating scale-2 standard test
Figure 2
Figure 2. ROC analysis of synucleins for autism diagnosis with ISAA
For α synuclein and α synuclein fold decrease, sensitivity was 93.6%, specificity was 74.3%, PPV was 92.9%, and NPV was 76.5% with a cutoff value of 5.38 and 5.45, respectively. ROC: receiver operating characteristics; AUC: area under the curve; ISAA: Indian Scale for Autism Assessment; PPV: positive predictive value; NPV: negative predictive value
Figure 3
Figure 3. ROC analysis - CARS-2 ST and synucleins
PPV: positive predictive value; NPV: negative predictive value; AUC: area under the curve; CARS-2 ST: childhood autism rating scale-2 standard test; ROC: receiver operating characteristics

Similar articles

References

    1. Early diagnosis of autism spectrum disorder: a review and analysis of the risks and benefits. Okoye C, Obialo-Ibeawuchi CM, Obajeun OA, et al. Cureus. 2023;15:0. - PMC - PubMed
    1. Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study. Raghavan K, Dedeepiya VD, Ikewaki N, Sonoda T, Iwasaki M, Preethy S, Abraham SJ. BMJ Neurol Open. 2022;4:0. - PMC - PubMed
    1. Plasma levels of alpha and gamma synucleins in autism spectrum disorder: an indicator of severity. Al-Mazidi S, Al-Ayadhi LY. Med Princ Pract. 2021;30:160–167. - PMC - PubMed
    1. The role of α-synuclein in neurotransmission and synaptic plasticity. Cheng F, Vivacqua G, Yu S. J Chem Neuroanat. 2011;42:242–248. - PubMed
    1. The alpha and beta synucleins: from pathophysiology to clinical application as biomarkers. Barba L, Paolini Paoletti F, Bellomo G, et al. Mov Disord. 2022;37:669–683. - PMC - PubMed

LinkOut - more resources